Vanguard Capital Management
ARQT icon

Vanguard Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Vanguard Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131M Buy
4,988,756
+117,220
+2% +$2.73M ﹤0.01% 1408
2026
Q1 		$115M Buy
+4,871,536
New +$124M ﹤0.01% 1395

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's ARQT Position: Q2 2026 in Review

Vanguard Capital Management increased its Arcutis Biotherapeutics (ARQT) stake by 2.4% in Q2 2026, buying an estimated $2.73M and bringing the position to 4,988,756 shares worth $131M. The position accounts for ﹤0.01% of the portfolio, ranked #1408.

Vanguard Capital Management first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Vanguard Capital Management held 4,988,756 shares of Arcutis Biotherapeutics worth $131M as of Q2 2026.
  • Vanguard Capital Management bought 117,220 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.73M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1408 holding.
  • Vanguard Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.